Looking Back at the Year in Research: 2019
The research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligable to try a new drug.
Radiation Therapy To Fight Pancreatic Cancer
Dr. Smith Apisarnthanarax, a radiation oncologist, details the different types of radiation therapy given to pancreatic cancer patients.
Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients
Dr. Michael Pishvaian explains how platinum-based therapy can improve the survival of pancreatic cancer patients with a specific mutation.
Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
Pancreatic Cancer Exceptional Responders and the Immune System Link
Dr. Vinod Balachandran looks at the immune system of exceptional responders--patients who respond extremely well to chemotherapy--for treatment clues.
Testing a Different Approach to Pancreatic Cancer Treatment
A pancreatectomy or Whipple procedure can remove a patient’s main tumor, but post-surgical testing of lymph nodes and the edges…
Genetic Testing for All Pancreatic Cancer Patients
A study by Dr. Gloria Petersen's research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
